Tags

Type your tag names separated by a space and hit enter

Delayed Anaphylaxis Involving IgE to Galactose-alpha-1,3-galactose.
Curr Allergy Asthma Rep 2015; 15(4):12CA

Abstract

Hypersensitivity in the allergic setting refers to immune reactions, stimulated by soluble antigens that can be rapidly progressing and, in the case of anaphylaxis, are occasionally fatal. As the number of known exposures associated with anaphylaxis is limited, identification of novel causative agents is important in facilitating both education and other allergen-specific approaches that are crucial to long-term risk management. Within the last 10 years, several seemingly separate observations were recognized to be related, all of which resulted from the development of antibodies to a carbohydrate moiety on proteins where exposure differed from airborne allergens but which were nevertheless capable of producing anaphylactic and hypersensitivity reactions. Our recent work has identified these responses as being due to a novel IgE antibody directed against a mammalian oligosaccharide epitope, galactose-alpha-1,3-galactose (alpha-gal). This review will present the history and biology of alpha-gal and discuss our current approach to management of the mammalian meat allergy and delayed anaphylaxis.

Authors+Show Affiliations

Department of Internal Medicine, Divisions of Allergy, Asthma and Immunology, University of Virginia Health System, PO Box 801355, Charlottesville, VA, 22908, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

26130470

Citation

Platts-Mills, Thomas A E., et al. "Delayed Anaphylaxis Involving IgE to Galactose-alpha-1,3-galactose." Current Allergy and Asthma Reports, vol. 15, no. 4, 2015, p. 12.
Platts-Mills TA, Schuyler AJ, Hoyt AE, et al. Delayed Anaphylaxis Involving IgE to Galactose-alpha-1,3-galactose. Curr Allergy Asthma Rep. 2015;15(4):12.
Platts-Mills, T. A., Schuyler, A. J., Hoyt, A. E., & Commins, S. P. (2015). Delayed Anaphylaxis Involving IgE to Galactose-alpha-1,3-galactose. Current Allergy and Asthma Reports, 15(4), p. 12. doi:10.1007/s11882-015-0512-6.
Platts-Mills TA, et al. Delayed Anaphylaxis Involving IgE to Galactose-alpha-1,3-galactose. Curr Allergy Asthma Rep. 2015;15(4):12. PubMed PMID: 26130470.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Delayed Anaphylaxis Involving IgE to Galactose-alpha-1,3-galactose. AU - Platts-Mills,Thomas A E, AU - Schuyler,Alexander J, AU - Hoyt,Alice E W, AU - Commins,Scott P, PY - 2015/7/2/entrez PY - 2015/7/2/pubmed PY - 2015/9/30/medline SP - 12 EP - 12 JF - Current allergy and asthma reports JO - Curr Allergy Asthma Rep VL - 15 IS - 4 N2 - Hypersensitivity in the allergic setting refers to immune reactions, stimulated by soluble antigens that can be rapidly progressing and, in the case of anaphylaxis, are occasionally fatal. As the number of known exposures associated with anaphylaxis is limited, identification of novel causative agents is important in facilitating both education and other allergen-specific approaches that are crucial to long-term risk management. Within the last 10 years, several seemingly separate observations were recognized to be related, all of which resulted from the development of antibodies to a carbohydrate moiety on proteins where exposure differed from airborne allergens but which were nevertheless capable of producing anaphylactic and hypersensitivity reactions. Our recent work has identified these responses as being due to a novel IgE antibody directed against a mammalian oligosaccharide epitope, galactose-alpha-1,3-galactose (alpha-gal). This review will present the history and biology of alpha-gal and discuss our current approach to management of the mammalian meat allergy and delayed anaphylaxis. SN - 1534-6315 UR - https://www.unboundmedicine.com/medline/citation/26130470/Delayed_Anaphylaxis_Involving_IgE_to_Galactose_alpha_13_galactose_ L2 - https://dx.doi.org/10.1007/s11882-015-0512-6 DB - PRIME DP - Unbound Medicine ER -